Sources of Heterogeneity in the Efficacy of Statins for Primary Prevention of Cardiovascular Diseases: A Systematic Review with Meta-Regression and Meta-Analysis of Within-Study Subgroup Differences
Cardiovascular Drugs and Therapy · 2026-10 · 40 (5) · 2049-2060
DOI: 10.1007/s10557-026-07883-6 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 02.05.2026. Verfasst von Yujun Long und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational Biology and Medical Big Data, Faculty of Computer Science and Artificial Intelligence, Shenzhen University of Advanced Te…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Primary Prevention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Program, Shenzhen Medical Research Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Evidence regarding sources of heterogeneity in the efficacy of statins for primary prevention of cardiovascular disease (CVD) remains limited. This study aimed to identify trial-level factors contributing to such heterogeneity. METHODS: Relevant studies were systematically identified from a previous systematic review and through searches in PubMed, Embase, and Cochrane up to 20 January 2026. The protocol was registered in PROSPERO (CRD42024579932). Randomized controlled trials (RCTs) in adults without prior CVD that investigated statin treatment were included. Risk of bias was assessed using the Cochrane Risk of Bias tool. Meta-analyses were conducted to pool risk ratios (RRs) and 95% confidence intervals (CIs) for major adverse cardiovascular events (MACE), myocardial infarction (MI), stroke, and cardiovascular death. Univariate meta-regression analyses were conducted to assess the impact of trial-level covariates on the effect sizes, expressed as the ratio of risk ratios (RRR). Within-study subgroup differences were meta-analyzed by pooling ratio of effect sizes. Meta-regression analyses were conducted using complete-case trial-level data. RESULTS: 25 RCTs (102,667 participants) were included. Compared to no statin treatment, statin treatment was associated with a reduced risk of MACE (RR, 0.73[95% CI, 0.67 to 0.80], P < 0.001), MI (RR, 0.68[95% CI, 0.60 to 0.77], P < 0.001), stroke (RR, 0.76[95% CI, 0.65 to 0.89], P = 0.001) and cardiovascular death (RR, 0.81[95% CI, 0.71 to 0.95], P = 0.008). Univariate meta-regression indicated that higher baseline total cholesterol (RRR, 1.29 [95% CI, 1.07 to 1.57], P = 0.008), higher low-density lipoprotein cholesterol (LDL-C) (RRR, 1.31 [95% CI, 1.07 to 1.62], P = 0.010), higher triglycerides (RRR, 1.81 [95% CI, 1.17 to 2.81], P = 0.008) and lower statin intensity (RRR, 0.74 [95% CI, 0.59 to 0.94], P = 0.015) were significantly associated with reduced efficacy of statins for stroke prevention at the trial level. CONCLUSIONS: Statin therapy demonstrated consistent efficacy in CVD prevention across diverse populations, except that baseline lipid profiles and statin intensity may represent exploratory, hypothesis-generating signals of potential effect modification for stroke prevention, warranting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Computational Biology and Medical Big Data, Faculty of Computer Science and Artificial Intelligence, Shenzhen University of Advanced Technology, Shenzhen, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
- Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, China.
- Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute, University of Nottingham Ningbo China, Ningbo, China.
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Förderung
- Shenzhen Science and Technology Innovation Program
- Shenzhen Medical Research Fund
- National Natural Science Foundation of China
Zitieren
APA
Long, Y., Liu, J., Cai, J., Zhuang, Q., Cai, T., Zhou, J., Chai, S., Lin, T., & Yang, Z. (2026). Sources of Heterogeneity in the Efficacy of Statins for Primary Prevention of Cardiovascular Diseases: A Systematic Review with Meta-Regression and Meta-Analysis of Within-Study Subgroup Differences. Cardiovascular Drugs and Therapy, 40(5), 2049-2060. https://doi.org/10.1007/s10557-026-07883-6
Vancouver
Long Y, Liu J, Cai J, Zhuang Q, Cai T, Zhou J, et al. Sources of Heterogeneity in the Efficacy of Statins for Primary Prevention of Cardiovascular Diseases: A Systematic Review with Meta-Regression and Meta-Analysis of Within-Study Subgroup Differences. Cardiovascular Drugs and Therapy. 2026;40(5):2049-2060. doi:10.1007/s10557-026-07883-6
BibTeX
@article{Long2026,
author = {Long, Yujun and Liu, Jianzhao and Cai, Jiaxin and Zhuang, Qiongqi and Cai, Ting and Zhou, Junwen and Chai, Sanbao and Lin, Tengfei and Yang, Zhirong},
title = {Sources of Heterogeneity in the Efficacy of Statins for Primary Prevention of Cardiovascular Diseases: A Systematic Review with Meta-Regression and Meta-Analysis of Within-Study Subgroup Differences},
journal = {Cardiovascular Drugs and Therapy},
year = {2026},
volume = {40},
number = {5},
pages = {2049--2060},
doi = {10.1007/s10557-026-07883-6}
}
EUVIMED